New schizophrenia drug enters final Long-Term safety testing
NCT ID NCT07369154
Summary
This study aims to check the long-term safety and side effects of a new medication called LB-102 for adults with stable schizophrenia. It will involve 900 participants who are not fully satisfied with their current antipsychotic medication and want to switch. The main goal is to see how well people tolerate the drug over a full year of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.